FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: NASDAQ:ARNA

Sort
E.g., 2013-05-21
E.g., 2013-05-21
Enter a comma separated list of user names.

ARNA, Arena Pharmaceuticals, Inc.

** ARNA and Eisai Inc. reported that the FDA has accepted for filing and review ARNA's resubmission of the New Drug Application for lorcaserin.

According to the company, the FDA considers the resubmission a complete, class 2 response, and assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

Crown Equity Holdings Inc. (OTCBB:CRWE) is pleased to announce its joint venture with Communication Expert Corporation.

The cornerstone of Crown Tele Services Inc. strategy is to meet the highest standards when it comes to delivering VoIP (Voice over Internet Protocol) communications solutions specifically designed to meet the business and residential market needs.

Proteonomix, Inc. (PROT.OB) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives.

PROT recently reported further developments with its Joint Venture Company, XGEN Medical LLC (”XGen”) towards implementing operations in the United Arab Emirates.

Brower Piven, A Professional Corporation reports that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of the common stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) during the period between December 8, 2008 and September 16, 2010, inclusive (the "Class Period").

ADVERTISE WITH US